Page 8 - Sun Pharma News Today

While the specialty pipeline is healthy and one of the drugs under review can potentially get launched in FY25, the growth outlook for FY25 appears dull

In Thursdays trading session on the BSE, shares of Sun Pharmaceutical Industries declined by 5%, reaching the days low of Rs 1,467. This drop occurred despite the company reporting a 34% year-on-year (YoY) increase in its Q4 profit to Rs 2,654.6 crore, with revenue rising by 10.1% YoY to Rs. 11,813 crore in Q4FY24.

GRSE, Elgi Rubber Co, Excel Realty N Infra, PG Electroplast and Cochin Shipyard, hit their fresh 52-week highs at 10:54AM.

(This story has not been edited by THE WEEK and is auto-generated from a PTI

Indian equity indices were trading in the green on Thursday after a flat start. At 9:40 a.m., Sensex was up 251 points or 0.34 per cent, at 74,472 points and Nifty was up 76 points or 0.34 per cent, at 22,674 points.Midcap and smallcap stocks ...

Mumbai, May 23 (IANS) Indian equity indices were trading in the green on Thursday after a flat start. At 9:40 a.m., Sensex was up 251 points or 0.34

Sun Pharma, Power Grid, Hindalco, JSW Steel and Grasim Inds. were among the top losers on NSE.

Sun Pharma numbers were slightly below expectations in terms of EBITDA and we do think that though they have guided for a very strong growth through their speciality portfolio, that is a little bit time away.

Notably, the management said that spending on R&D expenses will rise to 10% of revenue from 6-7% to aid its specialty portfolio

In Thursdays trading, Vedanta, Sun Pharma, NMDC, MFSL, and Hindalco witnessed a build-up of fresh short positions, signaling potential downward movement in stock prices.